Compare XRAY & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRAY | NBTX |
|---|---|---|
| Founded | 1899 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2009 | 2018 |
| Metric | XRAY | NBTX |
|---|---|---|
| Price | $8.32 | $26.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | $10.77 | ★ $53.35 |
| AVG Volume (30 Days) | ★ 4.9M | 138.3K |
| Earning Date | 11-05-2026 | 09-24-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 33.04 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.09 | $95.04 |
| P/E Ratio | $70.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.14 | $19.14 |
| 52 Week High | $14.76 | $57.14 |
| Indicator | XRAY | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 41.01 |
| Support Level | $8.23 | $24.49 |
| Resistance Level | $8.94 | $35.17 |
| Average True Range (ATR) | 0.54 | 2.20 |
| MACD | -0.15 | -0.50 |
| Stochastic Oscillator | 5.25 | 7.46 |
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantology. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.